Cizzle Bio, Inc.
LightNews LightNews
banner
cizzlebio.com
Cizzle Bio, Inc.
@cizzlebio.com
21 followers 23 following 160 posts
🔬 Detect Early. Save Lives.
Cizzle Bio, Inc. is a biotech company pioneering early cancer detection through advanced blood tests for lung & GI cancers.
cizzlebio.com
Posts Replies Media Videos
cizzlebio.com
Tonight, Cizzle Bio is joining the @preventcancer.org 2026 Annual Gala in Washington, D.C. We’re proud to support the Foundation’s cancer prevention and early detection work with a Bronze-Level pledge. Cizzle Biotechnology and CEO Allan Syms will also attend alongside Cizzle Bio and Bill Behnke.
Puerto Rico-themed event graphic announcing the Prevent Cancer Foundation’s 2026 Annual Gala tonight at the National Building Museum in Washington, D.C., with support from Cizzle Bio.
September 16, 2026 at 4:02 PM
cizzlebio.com
On September 16, Cizzle Bio will join the @preventcancer.org 2026 Annual Gala in Washington, D.C. We’re proud to support the event with a Bronze-Level pledge, and our Founder and CEO, Bill Behnke, is serving on the Gala Committee and assisted in securing key sponsors.
go.cizzlebio.com/fd3xDf
Puerto Rico-themed artwork for the Prevent Cancer Foundation’s 2026 Annual Gala, proudly supported by Cizzle Bio, on September 16 at the National Building Museum in Washington, D.C.
September 14, 2026 at 10:33 PM
cizzlebio.com
Mark your calendar for: our Director of Communications Berkley Behnke and lymphoma survivor Ella Behnke are joining "Blood Cancer Uncovered: Answers, Treatment and Support", a TikTok Live series from GLOW and Blood Cancer United. Sept 16 at 7 PM ET, live in the TikTok app at @GLOWONCOLOGY.
September 8, 2026 at 10:08 PM
cizzlebio.com
CIZ1B test is meant to support clinical assessment, not replace LDCT or clinical judgment.
For licensed providers in DFW and San Antonio, ordering setup steps are available here:
go.cizzlebio.com/SSj6gA
Graphic explaining that the CIZ1B blood test and LDCT imaging provide complementary information for lung cancer assessment — Cizzle Bio
September 4, 2026 at 10:28 PM
cizzlebio.com
New peer-reviewed research in The Journal of Applied Laboratory Medicine supports the CIZ1B biomarker blood test — 94% sensitivity, 97% NPV in the early-stage cohort, evaluating the recently launched commercialized assay. Read the press release: go.cizzlebio.com/5aPGDU
Cizzle Bio graphic announcing new peer-reviewed research in The Journal of Applied Laboratory Medicine supporting the CIZ1B Biomarker Blood Test for early lung cancer detection. The study reported 94% sensitivity and a 97% negative predictive value in the early-stage cohort, strengthening the scientific foundation for CIZ1B. The graphic reads, “Evidence that moves early detection forward.”
September 1, 2026 at 12:57 PM
cizzlebio.com
Provider FAQ: The CIZ1B Biomarker Blood Test can provide a biomarker-based tool to be used in conjunction with a comprehensive diagnostic assessment.
Review clinician resources and ordering setup steps:
go.cizzlebio.com/nDF5Ga
August 28, 2026 at 10:28 PM
cizzlebio.com
Cizzle Bio attended Next Generation DX Summit 2026, where Dr. Lary Robinson of Moffitt Cancer Center presented on the potential of the CIZ1B biomarker in earlier lung cancer detection.
Read our post-event recap and key takeaways from the presentation:
buff.ly/D4O2T54
@moffitnews.bsky.social
CIZ1B Biomarker Next Generation DX Summit 2026 Recap | Cizzle Bio, Inc.
Cizzle Bio recaps Dr. Lary Robinson’s Next Generation DX Summit 2026 presentation on CIZ1B, blood-based biomarkers, lung nodules, LDCT screening, and early lung cancer detection.
www.cizzlebio.com
August 28, 2026 at 12:57 AM
cizzlebio.com
CIZ1B Biomarker Blood Test clinician resources are available for licensed providers.
Review clinical information and ordering setup steps:
buff.ly/T4TeHfv
Cizzle Bio graphic promoting CIZ1B Biomarker Blood Test resources for licensed healthcare providers. Available resources include clinical performance, patient considerations, ordering setup, specimen collection, results access, patient education, and frequently asked questions. The design features a clinician displayed on a tablet alongside scientific imagery. Access clinician resources at https://www.cizzlebio.com/for-physicians/lung-cancer.
August 27, 2026 at 11:04 PM
cizzlebio.com
From the Next Generation Dx Summit: Dr. Lary Robinson of Moffitt Cancer Center presented on the CIZ1B blood biomarker for early lung cancer detection — and how it could help assess indeterminate lung nodules and reduce unnecessary invasive procedures. Full announcement: buff.ly/tMMQDb7
Cizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit
/PRNewswire/ -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced its participation in the...
www.prnewswire.com
August 26, 2026 at 11:55 PM
cizzlebio.com
We're heading to the Next Gen DX Summit 2026 in DC, Aug 24–26. On Monday at 11:15 AM EDT, Dr. Lary Robinson of Moffitt Cancer Center presents on the current clinical study underway at Moffitt Cancer and the clinical potential of the CIZ1B biomarker in early lung cancer detection.

buff.ly/ljgkWiL
Cizzle Bio will attend the 18th Annual Next Generation Dx Summit, August 24–26, 2026, at the Capital Hilton in Washington, D.C., and virtually. Dr. Lary Robinson of Moffitt Cancer Center will present “Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection” on August 24 at 11:15 a.m. EDT. The graphic features colorful wave patterns above the Washington Monument at dusk. Learn more at https://www.cizzlebio.com/events/next-generation-dx-summit-2026.
August 21, 2026 at 10:28 PM
cizzlebio.com
Provider FAQ: How do licensed clinicians get set up to order CIZ1B?

Providers in Dallas-Fort Worth and San Antonio, first step is account setup. Once setup is complete, physicians can access the provider portal to place orders and receive results.

Review the ordering setup steps:
buff.ly/W0VWQcT
Cizzle Bio provider-ordering guide graphic asking, “How can healthcare providers order the CIZ1B Lung Cancer Blood Test?” The image features a blood sample tube beneath a large question mark. Licensed providers can review setup steps and begin onboarding at https://www.cizzlebio.com/for-physicians/lung-cancer.
August 20, 2026 at 11:04 PM
cizzlebio.com
San Antonio, the CIZ1B Biomarker Blood Test for Lung Cancer is now available through licensed healthcare providers.
CIZ1B is designed to complement established diagnostic approaches, including LDCT, and support clinical decision-making.
Patients: buff.ly/GuYec8X
Clinicians: buff.ly/1zy9tqA
Cizzle Bio graphic announcing that the CIZ1B Biomarker Blood Test for earlier lung cancer detection is now available through licensed healthcare providers in San Antonio. The image features a South Texas map highlighting San Antonio, the Tower of the Americas, and a CIZ1B blood sample tube. Patient information: https://www.cizzlebio.com/for-patients/lung-cancer. Clinician resources: https://www.cizzlebio.com/for-physicians/lung-cancer.
August 12, 2026 at 11:55 PM
cizzlebio.com
Dallas-Fort Worth: CIZ1B is now available through licensed healthcare providers.
Patients can learn about CIZ1B and start a conversation with their healthcare provider:
buff.ly/GuYec8X
Clinicians can access ordering and clinical resources:
buff.ly/1zy9tqA
#CIZ1B #DallasHealthcare
Cizzle Bio graphic announcing that the CIZ1B Biomarker Blood Test for earlier lung cancer detection is now available through licensed healthcare providers across the Dallas–Fort Worth metropolitan area. The image features a Texas map highlighting Dallas and the North Texas skyline. Patient information: https://www.cizzlebio.com/for-patients/lung-cancer. Clinician resources: https://www.cizzlebio.com/for-physicians/lung-cancer.
August 11, 2026 at 10:08 PM
cizzlebio.com
The CIZ1B Biomarker Blood Test for Lung Cancer is designed to complement LDCT and other clinical information, not replace them.
Results should be interpreted by a healthcare provider as part of a comprehensive assessment.
Learn more: buff.ly/m5AToVS
#CizzleBio #CIZ1B #LungCancerFAQ #PatientEducation
Cizzle Bio carousel introducing frequently asked questions about the CIZ1B Biomarker Blood Test for earlier lung cancer detection. The graphic features a blood sample tube beneath a large question mark. “Does CIZ1B replace LDCT?” No. The CIZ1B Biomarker Blood Test is designed to complement low-dose computed tomography and other standard-of-care approaches, not replace them. “Does a CIZ1B result confirm or rule out cancer?” No. The test provides biomarker information that must be interpreted with other clinical information as part of a comprehensive assessment. “How is the test performed?” A small blood sample is collected, securely packaged and transported, then processed and analyzed by a CLIA-certified laboratory partner.
August 7, 2026 at 10:28 PM
cizzlebio.com
Primary care clinicians: CIZ1B adds biomarker data to lung cancer assessment alongside clinical judgment and appropriate imaging.
Dallas and San Antonio providers can begin CIZ1B ordering setup: buff.ly/1zy9tqA
#CIZ1B #PrimaryCare #LungCancer
Cizzle Bio clinician education graphic showing primary care’s role in earlier lung cancer detection. It presents three elements of clinical assessment: patient risk factors, appropriate imaging, and CIZ1B Biomarker Blood Test results as an additional data point supporting clinical decision-making. Dallas and San Antonio providers are invited to begin CIZ1B ordering setup.
August 6, 2026 at 10:08 PM
cizzlebio.com
Cizzle Bio is collaborating with BioBridge Global (BBG) to expand access to the CIZ1B Biomarker Blood Test for Lung Cancer across South Texas.

The minimally invasive blood test is designed to complement LDCT screening.

Read more: buff.ly/mld2Beq

#CIZ1B
Cizzle Bio and BBG Advanced Therapies announce a strategic laboratory collaboration to expand access to earlier lung cancer detection in South Texas. The graphic features a Texas map highlighting San Antonio and a blood sample tube. Graphic announcing a new laboratory collaboration in South Texas. BBG Advanced Therapies, a BioBridge Global subsidiary, will be an additional CLIA-certified laboratory offering the CIZ1B Biomarker Blood Test for Lung Cancer. U.S. map illustrating Cizzle Bio’s phased strategy to develop a national network of CLIA-certified laboratory partners. Texas is shown as the current foundation, with future partnerships intended to expand access across the country step by step. Cizzle Bio and BBG Advanced Therapies graphic describing the collaboration as a meaningful step forward for South Texas and Cizzle Bio’s commitment to earlier lung cancer detection. Read the full press release at https://www.prnewswire.com/news-releases/cizzle-bio-expands-access-to-early-lung-cancer-detection-through-strategic-laboratory-collaboration-with-biobridge-global-in-south-texas-302840705.html.
August 3, 2026 at 12:53 PM
cizzlebio.com
How does CIZ1B testing work?
A licensed provider orders the test, a blood sample is collected and analyzed through a CLIA-certified laboratory, and the provider interprets the result alongside imaging, patient history, and other clinical findings.
Patients: buff.ly/LnJBMtG
Cizzle Bio infographic titled “How CIZ1B Testing Works.” Four steps show a licensed healthcare provider ordering the test, collection of a blood sample of less than one tablespoon, analysis at a Dallas-based CLIA-certified laboratory, and clinical interpretation of the result alongside patient history, imaging, symptoms, risk factors, and other findings. Available through licensed healthcare providers in Dallas–Fort Worth and San Antonio. Learn more at https://www.cizzlebio.com/for-physicians/lung-cancer.
July 31, 2026 at 10:28 PM
cizzlebio.com
The CIZ1B Biomarker Blood Test for Lung Cancer does not replace LDCT.
It is designed to complement imaging and other clinical information by providing an additional biomarker-based tool to support patient assessment.
Learn more: buff.ly/04BfMtE

#CizzleBio #CIZ1B #LDCT #LungCancerScreening
Cizzle Bio graphic titled “CIZ1B + LDCT: Different tools. Complementary information.” An illustration pairs lungs representing LDCT imaging information with a CIZ1B blood sample tube representing biomarker information. The graphic states that CIZ1B supports—not replaces—established diagnostic approaches and that clinical decisions should consider the full clinical context. Learn more at https://www.cizzlebio.com/for-physicians/lung-cancer.
July 29, 2026 at 11:55 PM
cizzlebio.com
Lung cancer risk is not the same for everyone.
Smoking history matters, but family history, environmental exposure, chronic lung conditions, and other factors are also important.
Start a conversation with your healthcare provider: buff.ly/P2rVLbv
Cizzle Bio graphic featuring a woman with an anatomical lung overlay and the message, “Lung cancer risk is not the same for everyone. Know your risk. Ask questions.” Risk factors shown include smoking history, family history, radon and environmental exposure, chronic lung conditions, and age and overall health. The graphic encourages starting a conversation with a healthcare provider.
July 27, 2026 at 10:33 PM
cizzlebio.com
Healthcare providers in Dallas and San Antonio can now access clinical and ordering resources for the CIZ1B Biomarker Blood Test for Lung Cancer.
Review performance information, patient considerations, specimen requirements, and ordering instructions: buff.ly/04BfMtE
#CIZ1B #HealthcareProviders
Cizzle Bio graphic announcing that the CIZ1B test is available for clinician ordering in Dallas–Fort Worth and San Antonio. Resources cover clinical performance, patient considerations, ordering, specimen collection, results guidance, and patient education. A clinician holds a tablet beside a CIZ1B blood sample tube. Visit cizzlebio.com/for-physicians/lung-cancer.
July 24, 2026 at 10:28 PM
cizzlebio.com
CIZ1B is now commercially available to licensed healthcare providers across Dallas-Fort Worth and San Antonio following laboratory validation at OmniHealth Diagnostics.
Read the announcement: buff.ly/fKAKFGK
#CIZ1B #EarlyDetection
Cizzle Bio commercial launch announcement for the CIZ1B biomarker blood test for lung cancer. The test is now available through licensed healthcare providers in Dallas–Fort Worth and San Antonio following laboratory validation at OmniHealth Diagnostics. Graphic features a CIZ1B blood sample tube and a map of Texas highlighting both metropolitan areas.
July 22, 2026 at 12:28 PM
cizzlebio.com
Tomorrow marks an important step forward in Cizzle Bio’s mission to support earlier lung cancer detection.

More information is coming.

#CizzleBio #CIZ1B #DetectEarlySaveLives
July 21, 2026 at 10:08 PM
cizzlebio.com
CIZ1B has completed laboratory validation at OmniHealth Diagnostics, marking an important step toward clinical availability.

Cizzle Bio continues advancing CIZ1B as a minimally invasive biomarker blood test designed to support early lung cancer detection.

#CizzleBio #CIZ1B
July 8, 2026 at 11:55 PM
cizzlebio.com
Love Your Lungs Week is a reminder that lung health also means informed conversations, better tools, and earlier answers.

Cizzle Bio is advancing CIZ1B, a minimally invasive biomarker blood test designed to support lung cancer detection as an adjunct to LDCT and standard clinical assessment.
July 3, 2026 at 10:28 PM
cizzlebio.com
Love Your Lungs Week is a reminder to protect lung health, know your risk factors, and ask questions about early detection. At Cizzle Bio, we are advancing CIZ1B, a biomarker blood test for lung cancer coming soon to licensed U.S. healthcare providers. Protect your lungs. Know your risk.
June 29, 2026 at 10:33 PM